Reitz Katherine M, Gruen Danielle S, Guyette Frances, Brown Joshua B, Yazer Mark H, Vodovotz Yoram, Johanssen Pär I, Stensballe Jakob, Daley Brian, Miller Richard S, Harbrecht Brian G, Claridge Jeffrey, Phelan Herb A, Neal Matthew D, Zuckerbraun Brian S, Sperry Jason L
Department of Surgery, University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA.
Emergency Medicine, University of Pittsburgh, Pittsburgh, Pennsylvania, USA.
Trauma Surg Acute Care Open. 2021 Feb 11;6(1):e000648. doi: 10.1136/tsaco-2020-000648. eCollection 2021.
Prehospital plasma administration during air medical transport reduces the endotheliopathy of trauma, circulating pro-inflammatory cytokines, and 30-day mortality among traumatically injured patients at risk of hemorrhagic shock. No clinical data currently exists evaluating the age of thawed plasma and its association with clinical outcomes and biomarker expression post-injury.
We performed a secondary analysis from the prehospital plasma administration randomized controlled trial, PAMPer. We dichotomized the age of thawed plasma creating three groups: standard-care, YOUNG (day 0-1) plasma, and OLD (day 2-5) plasma. We generated HRs and 95% CIs for mortality. Among all patients randomized to plasma, we compared predicted biomarker values at hospital admission (T0) and 24 hours later (T24) controlling for key difference between groups with a multivariable linear regression. Analyses were repeated in a severely injured subgroup.
Two hundred and seventy-one patients were randomized to standard-care and 230 to plasma (40% YOUNG, 60% OLD). There were no clinically or statistically significant differences in demographics, injury, admission vital signs, or laboratory values including thromboelastography between YOUNG and OLD. Compared with standard-care, YOUNG (HR 0.66 (95% CI 0.41 to 1.07), p=0.09) and OLD (HR 0.64 (95% CI 0.42 to 0.96), p=0.03) plasma demonstrated reduced 30-day mortality. Among those randomized to plasma, plasma age did not affect mortality (HR 1.04 (95% CI 0.60 to 1.82), p=0.90) and/or adjusted serum markers by plasma age at T0 or T24 (p>0.05). However, among the severely injured subgroup, OLD plasma was significantly associated with increased adjusted inflammatory and decreased adjusted endothelial biomarkers at T0.
Age of thawed plasma does not result in clinical outcome or biomarker expression differences in the overall PAMPer study cohort. There were biomarker expression differences in those patients with severe injury. Definitive investigation is needed to determine if the age of thawed plasma is associated with biomarker expression and outcome differences following traumatic injury.
II.
在航空医疗转运期间进行院前血浆输注可减轻创伤性内皮病变、循环促炎细胞因子,并降低有失血性休克风险的创伤患者的30天死亡率。目前尚无临床数据评估解冻血浆的保存时间及其与伤后临床结局和生物标志物表达的关系。
我们对院前血浆输注随机对照试验PAMPer进行了二次分析。我们将解冻血浆的保存时间分为三组:标准治疗组、年轻(0-1天)血浆组和陈旧(2-5天)血浆组。我们生成了死亡率的风险比(HR)和95%置信区间(CI)。在所有随机接受血浆治疗的患者中,我们通过多变量线性回归比较了入院时(T0)和24小时后(T24)的预测生物标志物值,并控制了组间的关键差异。在重伤亚组中重复进行分析。
271例患者被随机分配至标准治疗组,230例被随机分配至血浆治疗组(40%为年轻血浆组,60%为陈旧血浆组)。年轻血浆组和陈旧血浆组在人口统计学、损伤情况、入院生命体征或实验室检查值(包括血栓弹力图)方面,在临床和统计学上均无显著差异。与标准治疗组相比,年轻(HR 0.66(95%CI 0.41至1.07),p=0.09)和陈旧(HR 0.64(95%CI 0.42至0.96),p=0.03)血浆组的30天死亡率降低。在随机接受血浆治疗的患者中,血浆保存时间不影响死亡率(HR 1.04(95%CI 0.60至1.82),p=0.90),也不影响T0或T24时根据血浆保存时间调整的血清标志物(p>0.05)。然而,在重伤亚组中,陈旧血浆在T0时与调整后的炎症生物标志物增加和调整后的内皮生物标志物减少显著相关。
在整个PAMPer研究队列中,解冻血浆的保存时间并未导致临床结局或生物标志物表达的差异。在重伤患者中有生物标志物表达差异。需要进行确定性研究以确定解冻血浆的保存时间是否与创伤后生物标志物表达及结局差异相关。
II级。